Zydus Lifesciences Reduces Buyback Size — Check Revised Price

Zydus Lifesciences Ltd. on Wednesday reduced the size of its buyback, the company said in its exchange filing. The pharmaceutical major has reduced the buyback shares to 87 lakh from the initial 96 lakh announced earlier in this month.

However, the company has hiked the buyback price to Rs 1,260 per share from Rs 1,150 per share. Promoters will also participate in the buyback, with May 29, 2026, fixed as the record date for determining the shareholder eligibility. As per the March quarter shareholding pattern, promoters of the company have a 75% stake in Zydus Life.

• 
  Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon
• 
  NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term
• 
  Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani
• 
  'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps
• 
  India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers
• 
  'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax
• 
  Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite
• 
  Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness
• 
  CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE
• 
  Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI

Zydus Lifesciences reported a consolidated net profit of Rs 1,272.5 crore for the March quarter, up 8.7% year-on-year. The topline or revenue from operations rose 16.2% year-on-year to Rs 7,587 crore from Rs 6,528 crore.

ALSO READ: Coal India OFS: Govt To Exercise Greenshoe Option To Sell Additional Rs 2,500-Crore Stake

Earnings Before Interest, Tax, Depreciation and Amortisation decreased 11.4% to Rs 1,919 crore from Rs 2,165 crore in the year-ago quarter, while Ebitda margin stood at 25.3% compared to 33.2% in the year-ago period. The pharma major registered a one-time loss of Rs 398 crore compared to Rs 220 crore in the corresponding period last year. The Ebitda is adjusted to forex gain.

Zydus Life Q4FY26 (Cons, YoY)

• Net Profit up 8.7% at Rs 1,273 crore versus Rs 1,171 crore YoY
• Revenue up 16.2% at Rs 7,587 crore versus Rs 6,528 crore YoY
• EBITDA down 11.4% at Rs 1,919 crore versus Rs 2,165 crore YoY
• EBITDA Margin at 25.3% versus 33.2% YoY
• One-time loss at Rs 398 crore versus loss of Rs 220 crore YoY
• Q4 EBITDA adjusted for forex gain

Zydus Lifescience Share Price Today

The earnings were announced after market close on Wednesday. The scrip closed 0.63% higher at Rs 1,085.80 apiece, this compares to a 0.03% decline in the NSE Nifty 50 index. During the day, the stock had risen as much as 0.91% to Rs 1,088.9 per share.

It has risen 18.27% in the last 12 months and 18.75% year-to-date.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.